Month: November 2013

Discriminant Value of Custom Ocular Response Analyzer Waveform Derivatives in Keratoconus – Corrected Proof

Purpose: To evaluate the performance of corneal hysteresis (CH), corneal resistance factor, and 16 investigator-derived Ocular Response Analyzer (ORA) variables in distinguishing keratoconus (KC) from the nondiseased state.Design: Retrospective case series.Participants: Fifty-four eyes of 27 unaffected patients and 49 eyes of 25 KC patients from the Instituto de Olhos, Rio de Janeiro, Brazil.Methods: Sixteen candidate variables were derived from exported ORA signals to characterize putative indicators of biomechanical behavior. Area under the receiver operating characteristic curve (AUC) and the Z statistic were used to compare diagnostic performance.Main Outcome Measures: Discriminant value of standard and derived ORA variables as measured by (Read more...)

Predicting Progression of Glaucoma from Rates of Frequency Doubling Technology Perimetry Change – Corrected Proof

Purpose: To evaluate the ability of longitudinal frequency doubling technology (FDT) to predict the development of glaucomatous visual field loss on standard automated perimetry (SAP) in glaucoma suspects.Design: Prospective, observational cohort study.Participants: The study included 587 eyes of 367 patients with suspected glaucoma at baseline selected from the Diagnostic Innovations in Glaucoma Study (DIGS) and the African Descent and Glaucoma Evaluation Study (ADAGES). These eyes had an average of 6.7±1.9 FDT tests during a mean follow-up time of 73.1±28.0 months.Methods: Glaucoma suspects had intraocular pressure (IOP) >21 mmHg or an optic disc appearance suspicious of glaucoma. All patients had normal (Read more...)

Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Results of the OPUS-1 Phase 3 Study – Corrected Proof

Purpose: To assess the efficacy and safety of lifitegrast ophthalmic solution 5.0% compared with placebo in subjects with dry eye disease.Design: Prospective, randomized, double-masked, placebo-controlled, parallel arm, multicenter clinical trial.Participants: A total of 588 adult subjects with dry eye disease.Methods: Eligible subjects were randomized 1:1 to receive topically administered lifitegrast (5.0%) or placebo (vehicle) twice daily for 84 days after a 14-day open-label placebo run-in period. After enrollment (day 0), subjects were evaluated at days 14, 42, and 84. Key objective (fluorescein and lissamine staining scores [Ora scales]) and subjective (Ocular Surface Disease Index [OSDI], 7-item visual analog scale, and ocular (Read more...)

Femtosecond laser-assisted cataract surgery linked to increased prostaglandin levels

Femtosecond laser-assisted cataract surgery was associated with increased prostaglandin concentrations in the aqueous humor, according to a study. Four studies were conducted; 113 patients underwent femtosecond laser-assisted cataract surgery, and 107 patients underwent conventional phacoemulsification and served as controls. After femtosecond laser pretreatment and at the beginning of conventional surgery, the investigators collected aqueous humor samples. Total prostaglandin and prostaglandin E2 concentrations were measured with an enzyme-linked immunoassay.

Risk for retinal detachment not increased with fluoroquinolones

Oral fluoroquinolone use did not lead to higher risk for retinal detachment, researchers from Statens Serum Institut in Copenhagen, Denmark, have found.“Given the limited power, this study can only rule out more than a threefold relative increase in the risk of retinal detachment associated with current fluoroquinolone use,” the researchers wrote in JAMA. “However, any differences in absolute risk are likely to have limited, if any, clinical significance.”